Zoetis Inc.
HealthcareNYSE:ZTS · New York Stock Exchange
-$1.18 today
Vol 3.59M · Avg 6.03M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
80.2%
avg 52.0%
ROIC
21.5%
avg 16.9%
ROA
17.3%
avg 13.0%
Analysis
ROE is currently the strongest return metric at 80.2% versus its period average of 52.0%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Kristin C. Peck | Chief Executive Officer & Director | $5.42M | — | 55 | $65,578.81 | 0.02% |
Wetteny N. Joseph | Executive Vice President & Chief Financial Officer | $1.80M | — | 54 | $9,792.30 | <0.01% |
Jamie Brannan | Executive Vice President & Chief Commercial Officer | $1.74M | — | 53 | $3,856.00 | <0.01% |
Robert J. Polzer | Scientific Advisor | $1.45M | — | 57 | $10,990.08 | <0.01% |
Roxanne Lagano | Executive Vice President, General Counsel & Corporate Secretary | $1.44M | — | 61 | $30,632.22 | <0.01% |
Rimma Driscoll | EVP of Global Strategy, Portfolio Mktg. & Business Dev and Global BioDevices & Platinum Performance | — | — | 53 | $6,035.75 | <0.01% |
Jared Shriver | President of U.S. Operations | — | — | — | — | — |
Julie A. Fuller | Executive Vice President, Chief Human Resources Officer & Global Operations | — | — | 53 | $1,798.04 | <0.01% |
Keith Sarbaugh | Executive Vice President & Chief Digital and Technology Officer | — | — | 47 | $2,105.19 | <0.01% |
Nick Ashton | Executive Vice President and President of Global Manufacturing & Supply | — | — | 52 | $2,214.00 | <0.01% |
Steven Frank | Vice President of Investor Relations | — | — | — | $21,458.00 | <0.01% |
Jeannette Ferran Astorga | Executive Vice President of Corporate Affairs & Chief Sustainability Officer | — | — | 50 | $2,250.83 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
3
$886,366.90
Sells
2
$2.54M
Net Sentiment
$1.65M
Net selling
Most Active
PECK KRISTIN C
2 transactions
Analysis
Insiders reported 3 buys worth $886,366.90 and 2 sells worth $2.54M over the last 12 months. That adds up to net selling of $1.65M. PECK KRISTIN C was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -7.9% | +19.1% (15yr)2 analysts |
| Revenue | N/A | N/A | +3.2% | +6.2% (15yr)13 analysts |
| Net Income | N/A | N/A | -8.0% | +18.2% (15yr)13 analysts |
| EBIT | N/A | N/A | +8.2% | +10.4% (15yr)13 analysts |
Analysis
Recent growth has been strongest in EBIT at +8.2% over three years. Forward estimates point to EPS at +19.1% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Elevance Health Inc.
NYSE:ELV
$87.54B
Cigna Corporation
NYSE:CI
$78.83B
Regeneron Pharmaceuticals, Inc.
NASDAQ:REGN
$63.39B
argenx SE
NASDAQ:ARGX
$55.59B
Cencora, Inc.
NYSE:COR
$54.89B
Becton, Dickinson and Company
NYSE:BDX
$52.81B
Takeda Pharmaceutical Company Limited
NYSE:TAK
$50.44B
IDEXX Laboratories, Inc.
NASDAQ:IDXX
$44.14B
Haleon plc
NYSE:HLN
$40.33B
Elanco Animal Health Incorporated
NYSE:ELAN
$12.11B
Who manages ZTS?
Zoetis Inc. (ZTS) lists 12 active executives. The top listed executive is Robert J. Polzer, Scientific Advisor.
Are ZTS insiders buying or selling?
Recent insider activity shows net buying of $30.07M.
Explore More
Continue the stock analysis
Jump to another research area for this company.